BioMed Valley Discoveries, Inc
BioMed Valley Discoveries, Inc
Explore linked clinical trials.6 results ยท Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Open-label Phase 1b Study of Ulixertinib and Cetuximab or Ulixertinib in Combination With Cetuximab and Encorafenib in Patients With Unresectable or Metastatic Colorectal Cancer Who Have Previously Received EGFR or BRAF-directed Therapy | Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, colonic disorder, colorectal neoplasm, digestive system disorder, digestive system neoplasm, intestinal disorder, neoplasm, rectal disorder | Recruiting | Phase 1 | 2026-09-11 | NCT05985954 | |
| Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors | Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Skin and Connective Tissue Diseases, endocrine system disorder, malignant endocrine neoplasm, malignant pancreatic neoplasm, melanocytic neoplasm, melanoma, neoplasm, neuroendocrine neoplasm, pancreas disorder, pancreatic neoplasm, primitive neuroectodermal tumor, skin disorder, skin neoplasm | Recruiting | Phase 1 | 2026-08-19 | NCT03454035 | |
| A Study of Ruxolitinib in Combination With Ulixertinib in People With Myelofibrosis | Hemic and Lymphatic Diseases, Myeloproliferative Disorders, bone marrow disorder, hematologic disorder, primary myelofibrosis | Recruiting | Phase 1 / Phase 2 | 2026-07-28 | NCT06773195 | |
| Window-of-Opportunity Trial of Ulixertinib for MAPK-Activated Gliomas | Neoplasms by Histologic Type, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, epithelial neoplasm, glioma, neoplasm, neuroepithelial neoplasm, primitive neuroectodermal tumor | Recruiting | Early phase 1 | 2026-06-12 | NCT05804227 | |
| Ulixertinib in People With Histiocytic Neoplasms | Histiocytic Neoplasms | Recruiting | Phase 2 | 2026-05-28 | NCT06411821 | |
| Pembrolizumab With Intratumoral Injection of Clostridium Novyi-NT | Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Neoplasms by Site, Skin and Connective Tissue Diseases, Urogenital Diseases, Urogenital Neoplasms, benign urinary system neoplasm, breast cancer, breast disorder, breast neoplasm, neoplasm, skin disorder, urinary system disorder | Active, not recruiting | Phase 1 | 2026-04-16 | NCT03435952 |